Business Wire

ADVA

9.4.2020 09:02:04 CEST | Business Wire | Press release

Share
Serverius deploys ADVA FSP 3000 TeraFlex™ for 1200G transport

ADVA (FSE: ADV) today announced that Serverius, one of the Netherlands’ largest data center service suppliers, is leveraging its FSP 3000 TeraFlex™ terminal to massively increase the capacity of its deployed infrastructure. By utilizing the industry’s most comprehensive and scalable solution, Serverius is answering fierce growth in demand for its connectivity, colocation and data security services. With its ultra-flexible bandwidth modulation, TeraFlex™ enables Serverius to harness previously unused spectrum, unlocking new value in its existing fiber network. The highly compact 1RU platform optimizes all optical paths and ensures the lowest cost per bit for all fiber links. By enabling super-channels of up to 1200Gbit/s and a total capacity of 7.2Tbit/s, TeraFlex™ empowers Serverius to provide Dutch and international enterprises with a new level of capacity and throughput.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200409005014/en/

“By harnessing the very latest innovation, we’re bringing a new level of bandwidth capacity and service quality to businesses throughout the Netherlands and beyond. The ADVA FSP 3000 TeraFlex™ is key to our mission of providing world-class data center connectivity. And, with its space- and power-efficiency, it also ensures that our services remain highly affordable today and sustainable for the future,” said Sergey Petukhin, head of connectivity infrastructure, Serverius. “This deployment unlocks the full potential of our network. Now we can meet rapidly rising data demand and be sure that our infrastructure is ready to scale when our clients need even more capacity. What’s more, the openness and programmability of TeraFlex™ mean that we’re free to harness the benefits of tomorrow’s innovation without being tied to any one vendor.”

Serverius’ new solution is built on the ADVA FSP 3000 TeraFlex™, which uses software-defined fractional QAM modulation and adaptive baud rate capabilities to support 1200Gbit/s streams. By retrieving optical channel conditions via network telemetry, the platform determines the best possible capacity and spectral efficiency for each light path. This enables Serverius to exploit untapped capacity in its existing infrastructure without the cost of a complete system upgrade. Each 1RU terminal can also support up to three cards, providing easy access to capacity up to 7.2Tbit/s. What’s more, Serverius is also harnessing ADVA’s MicroMux™QSFP28 plug, which converts 100GbE client ports into ten 10GbE ports, further reducing cost, rack space and operational complexity. Cloud solution specialists Exclusive Networks also played a key role in deploying the technology.

“Serverius has a clear vision of what businesses need and a bold strategy for delivering it. By leveraging our most advanced technologies to massively increase the capacity of its fiber plant, the Netherlands’ fastest-growing cloud connectivity provider is offering its customers a vital competitive edge. With our TeraFlex™, Serverius has the power to flexibly respond to soaring data requirements and help businesses achieve their full potential,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “The strong and long-lasting relationship we have with the Serverius team was also crucial to the success of this project. By working closely with their people, we’ve been able to ensure that the new solution meets all of their particular needs while maximizing the value of their deployed infrastructure.”

About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HUI (HUI:VSE) Merges Traditional and Crypto Finance: Commences Continuous Trading in Vienna With Leading Market Maker and Announces Impending Token Listing on Major Global Exchange15.6.2026 11:15:00 CEST | Press release

The first SaaS SuperApp for startups and VCs capitalizes on a $25M round a from Nimbus Capital and a +15% stock surge, unveiling a v3/v4 roadmap that bridges public equity with digital asset liquidity. HUI S.p.A., the pioneering vertical SuperApp and SaaS company dedicated to the global Venture Capital and startup ecosystem listed on the Vienna Stock Exchange, today released its global product strategy, marking an unprecedented convergence between traditional regulated markets and decentralized finance. Driven by a +15% stock surge and the consolidation of its $25 million round a equity commitment fully subscribed by global institutional fund Nimbus Capital, the company announced its upcoming transition to continuous trading on the Vienna market in partnership with a leading European market maker, alongside the activation of the initial PUT options tied to the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026061293689

Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 09:35:00 CEST | Press release

Agricultural innovation leader to contribute with agronomic expertise in building accurate crop health, pest forecasting and heat stress models India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of

Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release

The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover

LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release

AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye